166 related articles for article (PubMed ID: 22696815)
1. A cost analysis of first-line chemotherapy for low-risk gestational trophoblastic neoplasia.
Shah NT; Barroilhet L; Berkowitz RS; Goldstein DP; Horowitz N
J Reprod Med; 2012; 57(5-6):211-8. PubMed ID: 22696815
[TBL] [Abstract][Full Text] [Related]
2. Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174?
Miller CR; Chappell NP; Sledge C; Leath CA; Phippen NT; Havrilesky LJ; Barnett JC
Gynecol Oncol; 2017 Jan; 144(1):125-129. PubMed ID: 27816248
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Cost-Effectiveness Between Actinomycin D Versus Methotrexate-Folinic Acid in the Treatment of Low-Risk Gestational Trophoblastic Neoplasia.
Lertkhachonsuk AA; Hanvoravongchai P
J Reprod Med; 2016; 61(5-6):230-4. PubMed ID: 27424364
[TBL] [Abstract][Full Text] [Related]
4. Treatment of low-risk gestational trophoblastic neoplasia comparing biweekly eight-day Methotrexate with folinic acid versus bolus-dose Actinomycin-D, among Brazilian women.
Uberti EM; Fajardo Mdo C; da Cunha AG; Frota SS; Braga A; Ayub AC
Rev Bras Ginecol Obstet; 2015 Jun; 37(6):258-65. PubMed ID: 26200823
[TBL] [Abstract][Full Text] [Related]
5. Clinical epidemiology and management of gestational trophoblastic neoplasia in Hungary in the past 34 years.
Fülöp V; Szigetvári I; Szepesi J; Végh G; Singh M; Berkowitz RS
J Reprod Med; 2012; 57(7-8):310-8. PubMed ID: 22838247
[TBL] [Abstract][Full Text] [Related]
6. First line chemotherapy in low risk gestational trophoblastic neoplasia.
Alazzam M; Tidy J; Hancock BW; Osborne R
Cochrane Database Syst Rev; 2009 Jan; (1):CD007102. PubMed ID: 19160319
[TBL] [Abstract][Full Text] [Related]
7. Actinomycin D for methotrexate-failed low-risk gestational trophoblastic neoplasia.
Lurain JR; Chapman-Davis E; Hoekstra AV; Schink JC
J Reprod Med; 2012; 57(7-8):283-7. PubMed ID: 22838241
[TBL] [Abstract][Full Text] [Related]
8. First-line chemotherapy in low-risk gestational trophoblastic neoplasia.
Lawrie TA; Alazzam M; Tidy J; Hancock BW; Osborne R
Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD007102. PubMed ID: 27281496
[TBL] [Abstract][Full Text] [Related]
9. Weekly methotrexate (50mg/m(2)) without dose escalation as a primary regimen for low-risk gestational trophoblastic neoplasia.
Kang WD; Choi HS; Kim SM
Gynecol Oncol; 2010 Jun; 117(3):477-80. PubMed ID: 20347479
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of first-line single-agent chemotherapy regimens in low-risk gestational trophoblastic neoplasia: A network meta-analysis.
Li J; Li S; Yu H; Wang J; Xu C; Lu X
Gynecol Oncol; 2018 Feb; 148(2):247-253. PubMed ID: 29203174
[TBL] [Abstract][Full Text] [Related]
11. First-line chemotherapy in low-risk gestational trophoblastic neoplasia.
Alazzam M; Tidy J; Hancock BW; Osborne R; Lawrie TA
Cochrane Database Syst Rev; 2012 Jul; 7(7):CD007102. PubMed ID: 22786502
[TBL] [Abstract][Full Text] [Related]
12. Importance of salvage therapy in the management of high-risk gestational trophoblastic neoplasia.
Lurain JR; Schink JC
J Reprod Med; 2012; 57(5-6):219-24. PubMed ID: 22696816
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: The New England Trophoblastic Disease Center experience.
Maestá I; Nitecki R; Horowitz NS; Goldstein DP; de Freitas Segalla Moreira M; Elias KM; Berkowitz RS
Gynecol Oncol; 2018 Jan; 148(1):161-167. PubMed ID: 29092742
[TBL] [Abstract][Full Text] [Related]
14. Low-risk gestational trophoblastic neoplasia and methotrexate resistance: predictors of response to treatment with actinomycin D and need for combination chemotherapy.
Growdon WB; Wolfberg AJ; Goldstein DP; Feltmate CM; Chinchilla ME; Lieberman ES; Berkowitz RS
J Reprod Med; 2010; 55(7-8):279-84. PubMed ID: 20795339
[TBL] [Abstract][Full Text] [Related]
15. Treatment of nonmetastatic and metastatic low-risk gestational trophoblastic neoplasia: factors associated with resistance to single-agent methotrexate chemotherapy.
Chapman-Davis E; Hoekstra AV; Rademaker AW; Schink JC; Lurain JR
Gynecol Oncol; 2012 Jun; 125(3):572-5. PubMed ID: 22449733
[TBL] [Abstract][Full Text] [Related]
16. 30 years' experience in the treatment of low-risk gestational trophoblastic neoplasia in Hungary.
Fülöp V; Szigetvári I; Szepesi J; Végh G; Bátorfi J; Nagymányoki Z; Török M; Berkowitz RS
J Reprod Med; 2010; 55(5-6):253-7. PubMed ID: 20626182
[TBL] [Abstract][Full Text] [Related]
17. Methotrexate on a 21-day cycle for low-risk gestational trophoblastic neoplasia.
Diaz J; Thomas MB; Paz-Pabon C; Hernandez E
J Reprod Med; 2012; 57(9-10):411-4. PubMed ID: 23091988
[TBL] [Abstract][Full Text] [Related]
18. Combined methotrexate-dactinomycin: an effective therapy for low-risk gestational trophoblastic neoplasia.
Eiriksson L; Wells T; Steed H; Schepansky A; Capstick V; Hoskins P; Pike J; Swenerton K
Gynecol Oncol; 2012 Mar; 124(3):553-7. PubMed ID: 22079360
[TBL] [Abstract][Full Text] [Related]
19. Comparison of pulsed actinomycin D and 5-day actinomycin D as first-line chemotherapy for low-risk gestational trophoblastic neoplasia.
Mu X; Song L; Li Q; Yin R; Zhao X; Wang D
Int J Gynaecol Obstet; 2018 Nov; 143(2):225-231. PubMed ID: 30051913
[TBL] [Abstract][Full Text] [Related]
20. Treatment for low-risk gestational trophoblastic disease: comparison of single-agent methotrexate, dactinomycin and combination regimens.
Abrão RA; de Andrade JM; Tiezzi DG; Marana HR; Candido dos Reis FJ; Clagnan WS
Gynecol Oncol; 2008 Jan; 108(1):149-53. PubMed ID: 17931696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]